SAN DIEGO, May 12, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that it will present new analyses of Phase 2 data of the investigational drug crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) and post hoc analyses of Phase 3 data for EFMODY (hydrocortisone modified-release hard capsules). EFMODY is approved by the European Commission for the European Economic Area (including Northern Ireland) (EEA) and by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of adults and adolescents (12 years and older) with CAH. These new data and an additional poster showing Phase 2 data of crinecerfont in adolescents with classic CAH will be presented at ECE 2023, the 25th European Congress of Endocrinology in Istanbul, Turkey from May 1316.
In previously reported Phase 2 study data, crinecerfont treatment for 14 days led to clinically meaningful reductions of 17hydroxyprogesterone (17OHP), adrenocorticotropic hormone (ACTH), and androstenedione in adults with classic CAH due to 21-OHD. Post hoc analyses of these data released today assessed whether baseline hormone levels and glucocorticoid (GC) doses correlated with treatment response. A strong correlation was found between baseline level and change from baseline to Day 14 for 17OHP, ACTH, and androstenedione, with the greatest reductions from baseline observed in subjects with the highest baseline hormone level. These results indicate that adults with classic CAH who have more elevated baseline hormone levels have the potential for a greater response to treatment with crinecerfont. However, reductions in androgen levels were seen in patients regardless of their GC dose at baseline. See the abstract (Poster #274; Response to Crinecerfont Treatment in Adults with Classic Congenital Adrenal Hyperplasia is Correlated with Elevated Baseline Hormone Levels, but Not Glucocorticoid Dose) for more information here.
"Androgen excess is a hallmark feature of classic congenital adrenal hyperplasia. These analyses demonstrate that the effectiveness of crinecerfont in reducing androgen levels in this study correlated with baseline hormone level, irrespective of GC dose. Patients with higher baseline androgens experienced greater reductions following treatment with crinecerfont, which supports the potential of crinecerfont in providing improved androgen control across a broad range of CAH patients," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. "We plan to announce top-line data from our Phase 3 CAHtalyst clinical studies of crinecerfont in children, adolescents, and adults in the fourth quarter of 2023."
Treatment of adults with crinecerfont was generally well tolerated with no related serious adverse events reported. Adverse events reported in two or more participants included headache, upper respiratory tract infection, fatigue, contusion (bruising), insomnia,nasopharyngitis, pyrexia, and nausea.
EFMODY has been shown to replicate the natural circadian rhythm of cortisol and reduce androgen levels in CAH patients. In a Phase 3 study, adults with classic CAH were randomized to continue standard therapy with immediate-release hydrocortisone or receive EFMODY modified-release hydrocortisone capsules (MRHC) at the same hydrocortisone dose equivalent. In the MRHC group, it was found that MRHC (which demonstrated similar bioavailability to immediate-release hydrocortisone) provided a greater reduction in 17-OHP standard deviation score 24-hour profile than was seen in the standard therapy group. The more physiological exposure pattern provided by MRHC means that patients previously on other GC therapy, experienced greater reduction in androgen levels at an equivalent dose of MRHC. These data will be part of an oral presentation (Oral Presentation, May 15, 2:202:30pm: Switching Patients with Congenital Adrenal Hyperplasia to Modified-Release Hydrocortisone Capsules: Relative Bioavailability and Disease Control). See more information here.
"Findings of these new analyses of the EFMODYstudy provide prescribing physicians with dosing guidance for this alternative to immediate-release hydrocortisone, which reduces androgen levels at similar dose levels, while replicating cortisol diurnal rhythm in patients with CAH," Dr. Roberts added.
In the entire EFMODY development clinical trial program, the overall most common serious adverse events were acute adrenal insufficiency (4.2 percent of patients treated with EFMODY). Other common reactions in relation to EFMODY were fatigue (11.7 percent of patients), headache (7.5 percent), increased appetite (5.8 percent), dizziness (5.8 percent) and increased weight (5.8 percent).
Additional Presentation:
Selected as one of the Top 40 Posters at ECE(Poster #P1); Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, Lowers Adrenal Androgens and Precursors in Adolescents with Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences is developing crinecerfont, an investigational, oral, steroid-independent, selective corticotropin-releasing factor type 1 receptor (CRF1) antagonist for the treatment of classic CAH due to 21-OHD. Neurocrine has completed enrollment in Phase 3 global registrational studies of crinecerfont in adults (18 years of age and older) and children and adolescents (2 to 17 years of age) with classic CAH, called the CAHtalyst and CAHtalyst Pediatric studies, respectively.As part of the CAHtalyst clinical trial program, participants who complete these trials will be able to continue to receive crinecerfont as part of an open-label extension.
Classic CAH is a rare autosomal disease caused by a genetic defect in one of the enzymes (21-OHD) involved in the production of adrenal hormones. The disorder is characterized by cortisol deficiency and often also aldosterone deficiency, elevated adrenocorticotropic (ACTH) levels, and excess production of adrenal androgens (including androstenedione). Cortisol deficiency can lead to adrenal crises, while androgen excess can lead to virilization in females, abnormalities in growth leading to short stature, early puberty, and infertility.
EFMODYwas developed by Diurnal Ltd. and is a preparation of hydrocortisone that has been specifically designed to replicate the natural circadian rhythm of cortisol, when given in a twice-a-day "toothbrush" regimen, (administered last thing at night before sleep and first thing in the morning on waking), to improve androgen control and chronic fatigue in patients with cortisol deficiency. It is a multi-particulate formulation presented as a capsule and is available in doses of 5 mg and 10 mg. Neurocrine Biosciences acquired Diurnal Group plc. in November 2022.
About Classic Congenital Adrenal Hyperplasia (CAH)Congenital adrenal hyperplasia (CAH) refers to a group of genetic conditions that result in an enzyme deficiency that alters the production of adrenal hormones. Approximately 95 percent of CAH cases are caused by a mutation that leads to deficiency of the enzyme 21-hydroxylase (21-OHD). In classic CAH, severe deficiency of this enzyme leads to an inability of the adrenal glands to produce cortisol and, in approximately 75 percent of cases, aldosterone. If left untreated, classic CAH can result in salt wasting, dehydration, and even death.
There are currently no steroid-independent treatments approved by the U.S. Food and Drug Administration (FDA) for classic CAH. Glucocorticoids, the current standard of care, are used to correct the endogenous cortisol deficiency and to try to reduce the high adrenocorticotropic hormone (ACTH) levels resulting in androgen excess. However, standard glucocorticoid treatment at dosing well above the normal physiological level for androgen control has been associated with serious and significant complications of steroid excess, including metabolic abnormalities, increased cardiovascular risk, bone loss, fractures, growth impairment, muscle weakness, and increased infection risk. Androgen excess has been associated with virilization in females, abnormalities in growth leading to short stature, early puberty, and infertility.
To learn more about CAH, click here.
About CrinecerfontCrinecerfont is an investigational, oral, steroid-independent, selective corticotropin-releasing factor type 1 receptor (CRF1) antagonist under evaluation for the treatment of classic CAH due to 21-hydroxylase deficiency (21-OHD). Antagonism of CRF1 receptors in the pituitary has been shown to decrease adrenocorticotropic hormone (ACTH) levels, which in turn could decrease the production of adrenal androgens and potentially the symptoms associated with classic CAH. Research also suggests that lowering androgen levels may enable lower, more physiologic dosing of glucocorticoids and thus potentially reduce the complications associated with exposure to greater than normal glucocorticoid doses in patients with classic CAH.
To learn more about crinecerfont, click here.
About CAHtalyst StudiesNeurocrine Biosciences has completed enrollment in Phase 3 global registrational studies of crinecerfont in adults (18 years of age and older) and children and adolescents (ages 2 to 17 years of age) with classic CAH. As part of the CAHtalystclinical trial program, participants who completed these trials will be able to continue to receive crinecerfont as part of an open-label extension. We plan to announce top-line data from our Phase 3 CAHtalyst clinical studies in the fourth quarter of 2023.
Treatment with crinecerfont was generally well tolerated in adolescent and adult participants with no related serious adverse events or discontinuations due to adverse events. Treatment-emergent adverse events reported in two or more participants included headache, dizziness,upper respiratory tract infection, fatigue, contusion (bruising), insomnia, nasopharyngitis, pyrexia, and nausea.
For more information about the adult CAHtalyst Phase 3 study, please visit cahtalyst.cahstudies.comand ClinicalTrials.gov.
For more information about the pediatric CAHtalyst Phase 3 study, please visit cahtalystpeds.cahstudies.comand ClinicalTrials.gov.
AboutEFMODYEFMODY is a modified-release preparation of hydrocortisone that has been specifically designed to replicate the natural circadian rhythm of cortisol when given in a twice-a-day "toothbrush" regimen (last thing at night before sleep and first thing in the morning on waking) to reduce excess androgens and chronic fatigue in patients with diseases of cortisol deficiency. In 2021, EFMODY received marketing authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain (England, Wales, and Scotland) and from the European Commission in the European Economic Area (including Northern Ireland).
About Neurocrine BiosciencesNeurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visitneurocrine.com, and follow the company on LinkedIn, Twitter and Facebook. (*in collaboration with AbbVie)
Neurocrine and the Neurocrine logo are registered trademarks and CAHtalyst is a trademark of Neurocrine Biosciences, Inc. EFMODY is a registered trademark of Diurnal Ltd.
Neurocrine Biosciences Forward-Looking StatementIn addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits of crinecerfont to patients and future clinical development plans as well as statements regarding the potential benefits to be derived from certain of our products. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements include: our future financial and operating performance; risks and uncertainties associated with the commercialization of our products; the risk that our products and/or product candidates will not be found to be safe and/or effective or may not prove to be beneficial to patients; that development activities for our products and/or product candidates may not be completed on time or at all; risks that clinical development activities may be delayed for regulatory or other reasons, may not be successful or replicate previous and/or interim clinical trial results, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that regulatory submissions for our products and/or product candidates may not occur or be submitted in a timely manner; risks that our products and/or product candidates may not obtain regulatory approvals; or that theU.S. Food and Drug Administrationor regulatory authorities outside theU.S.may make adverse decisions regarding our products and/or product candidates; risks and uncertainties relating to competitive products and technological changes that may limit demand for our products; risks associated with our dependence on third parties for development and manufacturing activities related to our products and our product candidates, and our ability to manage these third parties; and other risks described in the Company's periodic reports filed with theSecurities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter endedMarch 31, 2023.Neurocrine Biosciencesdisclaims any obligation to update the statements contained in this press release after the date hereof.
SOURCE Neurocrine Biosciences, Inc.
Read more from the original source:
Neurocrine Biosciences Presents Data on Treatment of Patients with ... - PR Newswire
- Tango Parkinson's Therapy (Washington U. in St. Louis) - May 7th, 2011 [May 7th, 2011]
- Parkinson's Disease Treatment-Exercise Program-Part 2 of 4 - May 14th, 2011 [May 14th, 2011]
- Parkinson's Disease Stem Cell Treatment - Part 2 - May 21st, 2011 [May 21st, 2011]
- Deep Brain Stimulation treatment for Parkinson's disease - May 22nd, 2011 [May 22nd, 2011]
- Parkinson's Disease Treatment-Exercise Program-Part 4 of 4 - May 24th, 2011 [May 24th, 2011]
- James, Parkinson's disease, after stem cell treatment at Tiantan Puhua Hospital Beijing - May 30th, 2011 [May 30th, 2011]
- Parkinson's Disease Stem Cell Treatment - Part 1 - May 30th, 2011 [May 30th, 2011]
- Parkinson's Disease Treatment -- Mayo Clinic - June 2nd, 2011 [June 2nd, 2011]
- When should I start treatment if I have Parkinson's Disease? - June 3rd, 2011 [June 3rd, 2011]
- parkinson-treatment-with-cupping-4.flv - June 3rd, 2011 [June 3rd, 2011]
- New treatment options for Parkinson's Disease feat. Nashville Predators coach Brent Peterson - June 8th, 2011 [June 8th, 2011]
- Speech Treatment in Parkinson disease: Sharon Kha's Story - June 8th, 2011 [June 8th, 2011]
- How you can help cure Parkinson's - June 9th, 2011 [June 9th, 2011]
- TV9 - LADIES CLUB : "PARKINSON DISEASE" - CAUSE, SYMPTOMS - June 9th, 2011 [June 9th, 2011]
- Parkinson's Treatment: Case #1 - June 12th, 2011 [June 12th, 2011]
- parkinsons cure - June 17th, 2011 [June 17th, 2011]
- A Parkinson Patient Finds their Miracle. FCR Treatment helps Parkinson's Disease. - July 3rd, 2011 [July 3rd, 2011]
- Parkinson's Treatment: Case #2 - July 15th, 2011 [July 15th, 2011]
- TMJ Treatment Helping with Parkinson's Symptoms Dr. Gary Demerjian Burbank, California - July 15th, 2011 [July 15th, 2011]
- Parkinson's Treatment at Ta'ir Laser Center testimonial - July 16th, 2011 [July 16th, 2011]
- Parkinson's Disease client pre and post treatment - July 17th, 2011 [July 17th, 2011]
- Parkinson's Disease: Diagnosis, Causes and Treatment. Part 2 - July 18th, 2011 [July 18th, 2011]
- Parkinson's Disease: Diagnosis, Causes and Treatment part4 - July 18th, 2011 [July 18th, 2011]
- Glutathione for Parkinson's Disease. Learn why it helps symtoms - July 18th, 2011 [July 18th, 2011]
- Parkinson's Disease: Diagnosis, Causes and Treatment. - July 19th, 2011 [July 19th, 2011]
- parkinson-treatment-with-cupping-1.flv - July 20th, 2011 [July 20th, 2011]
- 7.30 - a treatment for Parkinson's Disease can cause problem gambling - July 27th, 2011 [July 27th, 2011]
- Parkinson's Disease Symptoms Improve with Non-Surgical TMJ Treatment: Dr. Gary Demerjian - July 29th, 2011 [July 29th, 2011]
- Werth Parkinson Centre, Daniella - Treatment - August 4th, 2011 [August 4th, 2011]
- 6.30 - Parkinson's treatment - August 19th, 2011 [August 19th, 2011]
- MDTV: New Drug Treatments for Parkinson's Disease - September 10th, 2011 [September 10th, 2011]
- Pakistan Parkinson's Disease patient Treatment, in chennai Surgery hospital - DINAMALAR - September 23rd, 2011 [September 23rd, 2011]
- Parkinson's treatment gives life back - October 2nd, 2011 [October 2nd, 2011]
- Parkinson Doctor Sarasota Discusses Parkinson's Disease Treatments - Video - October 15th, 2011 [October 15th, 2011]
- New treatments for Parkinson's disease - pt 1 - Video - October 16th, 2011 [October 16th, 2011]
- Parkinson's Disease Treatment - Year and a Half Later... - Video - October 19th, 2011 [October 19th, 2011]
- Still Life: The Search for a Parkinson's Cure - Video - October 22nd, 2011 [October 22nd, 2011]
- Can Exercise Treat Parkinson's? - Video - October 30th, 2011 [October 30th, 2011]
- Parkinsons Treatments | Symptoms Parkinsons - Video - November 2nd, 2011 [November 2nd, 2011]
- Symptoms - November 3rd, 2011 [November 3rd, 2011]
- Revolutionary Treatment for Parkinson's - Video - November 4th, 2011 [November 4th, 2011]
- Herbal Treatment for Parkinsons disease and recovery - Video - November 7th, 2011 [November 7th, 2011]
- Early Diagnosis and Treatment of Parkinson's Disease - Video - November 10th, 2011 [November 10th, 2011]
- Parkinson's Disease Treatment (part 1 of 4) at Penn Medicine - Video - November 15th, 2011 [November 15th, 2011]
- Parkinson's Disease Treatment - Video - November 18th, 2011 [November 18th, 2011]
- MDTV: Parkinson's Disease: Treating Off Times - Video - November 20th, 2011 [November 20th, 2011]
- parkinson-treatment-with-hijamah-therapy.3gp - Video - November 24th, 2011 [November 24th, 2011]
- parkinson-treatment-with-cupping-2.flv - Video - December 3rd, 2011 [December 3rd, 2011]
- Parkinsons Antioxident treatment before with Dr. Offutt.MOV - Video - December 7th, 2011 [December 7th, 2011]
- Teva Presenting Data on MS and Parkinson's Disease Treatments - Video - December 7th, 2011 [December 7th, 2011]
- LSVT® LOUD Treatment Benefits Parkinson's Disease Patient -- Hendricks Regional Health - Video - December 14th, 2011 [December 14th, 2011]
- Parkinson's Cure - Dating - Video - December 21st, 2011 [December 21st, 2011]
- Parkinson's Treatment part-2 - Video - December 29th, 2011 [December 29th, 2011]
- Parkinson's Treatment - Video - January 1st, 2012 [January 1st, 2012]
- Parkinson's Treatment - Deep Brain Stimulation - Video - January 2nd, 2012 [January 2nd, 2012]
- Parkinson's cure with out medicine - Video - January 10th, 2012 [January 10th, 2012]
- Parkinson's Disease and The Argentine Tango - Video - January 11th, 2012 [January 11th, 2012]
- Parkinson treatment shows positive results in clinical testing - Video - January 15th, 2012 [January 15th, 2012]
- Parkinson's Disease Treatment - Patient Testimony "Lad" - Video - January 27th, 2012 [January 27th, 2012]
- Parkinson - Video - January 27th, 2012 [January 27th, 2012]
- parkinson-treatment-with-cupping-3.flv - Video - January 28th, 2012 [January 28th, 2012]
- Parkinson's Disease: Balance, Gait (Walk) and Tremors Improve with New Non-Surgical Treatment Part 2 - Video - January 29th, 2012 [January 29th, 2012]
- Researchers visualize the development of Parkinson's cells - January 31st, 2012 [January 31st, 2012]
- NPH diagnosis in San Tan Valley man returns him to normal life - January 31st, 2012 [January 31st, 2012]
- Laser targeting could help fight Parkinson's - February 1st, 2012 [February 1st, 2012]
- Study of live human neurons reveals Parkinson's origins - February 7th, 2012 [February 7th, 2012]
- Lauren Sciences LLC awarded MJFF grant to develop a V-SmartTM therapeutic for Parkinson's disease - February 7th, 2012 [February 7th, 2012]
- "Biochemistry", Advances in Parkinson's Disease Treatment - Video - February 7th, 2012 [February 7th, 2012]
- Parkinson's Disease Symptoms Improve with Non-Surgical TMJ Treatment: Part 2 - Video - February 7th, 2012 [February 7th, 2012]
- Treatment of Parkinson's Disease Symptoms - Video - February 7th, 2012 [February 7th, 2012]
- Parkinson Disease - Surgical Treatment - Video - February 8th, 2012 [February 8th, 2012]
- MediGait Announces: GaitAid Device for Parkinson's Disease Shows Significant Step-initiation Improvement in New Trial ... - February 14th, 2012 [February 14th, 2012]
- Tai Chi Makes Parkinson’s Patients Steadier on Feet, Study Says - February 14th, 2012 [February 14th, 2012]
- Cleveland Clinic Joins 23andMe in the Search for Genetic Clues to Parkinson's Disease - February 14th, 2012 [February 14th, 2012]
- Cleveland Clinic to Recruit Parkinson's Patients for 23andMe - February 14th, 2012 [February 14th, 2012]
- Fairhope Parkinson's patient enters film in contest to awareness of disease - February 15th, 2012 [February 15th, 2012]
- Tai Chi may help Parkinson's patients regain balance - February 16th, 2012 [February 16th, 2012]
- Weight Training May Help Parkinson's Patients Retain Function - February 17th, 2012 [February 17th, 2012]
- Parkinson's Disease and Exercise: How Much Is Beneficial? - February 17th, 2012 [February 17th, 2012]
- Study shows exercise may help Parkinson's patients - February 17th, 2012 [February 17th, 2012]